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Relation between bone mineral density and serum ferritin levels  
in patients with thalassemia major 
 
 
Abstract: 
Background: Thalassemia/haemoglobinopathy is a hereditary disease 
with increased erythropoiesis and expansion of the bone marrow cavity. 
Consequently, there is a reduction in trabecular bone tissue resulting in 
osteopenia/osteoporosis. The present study was performed to determine 
bone mineral density (BMD) in children and adolescents with major 
thalassemia and its correlation with serum ferritin level. 
Methods: Seventy children and adolescents with major thalassemia were 
divided into two groups, (each group with 35 patients). Patients with 
serum ferritin level more than 1500 ng/dl were defined as case group and 
those with serum ferritin level lower than 1500 ng/dl were defined as 
control group. Thyroid and parathyroid function tests were performed as 
well as calcium and phosphorus serum level were checked. Dual X-ray 
Absorptiometry (DXA) was the diagnostic test for osteoporosis. Only 
patients with transfusion-dependent thalassemia major were enrolled. 
Patients with delayed puberty, hypothyroidism or parathyroid 
dysfunction, renal failure, liver failure, growth hormone deficiency and 
also those who used Calcitriol were excluded from the research. 
Results: Results showed that the mean serum ferritin in patients who had 
femoral osteoporosis was higher from those with osteopenia and normal 
density in the femur. (p=0.001). In addition, the mean serum ferritin in 
patients with vertebral osteoporosis was higher than that in those with 
osteopenia and normal bone density in the vertebral bones, (p=0.002). 
There is a significant difference between serum ferritin in different bone 
densities. 
Conclusions: Bone density is a good indicator of bone status in patients 
with major thalassemia and we recommend measuring it annually. 
Keywords: beta-Thalassemia Major, Absorptiometry-Photon, Bone 
Density, Osteoporosis, Ferritin 
 
 
 
 
 
 
Introduction: 
Thalassemia is a hereditary disease that causes imbalanced production 
of globin chains. This disorder causes inefficient erythropoiesis as well as 
increased peripheral hemolysis. Because of the increased inefficient 
erythropoiesis, the bone marrow cavity becomes larger, and cortical and 
tubular parts of the bone tissue will decrease 
[1, 2]
. Thus, thalassemia 
patients will develop multiple bone disorders including bone pain, bone 
deformities, delayed bone growth, growth retardation, rickets 
disease, scoliosis, spinal deformities, pathological fractures, osteopenia 
and osteoporosis 
[3, 4]
. Osteoporosis is defined as bone tissue loss and 
degradation of the bone skeleton, which leads to reduced bone strength 
and increased risk of bone fractures
 [5]
. 
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Bone mineral density (BMD) is a good indicator for 
assessment of bone status and the most important 
predictor of childhood thalassemia 
[6]
, which can be 
fatal. However, treatment with blood transfusions can 
play a crucial role in reducing mortality and 
morbidities as well as enhancing the quality of life and 
increased longevity of these patients 
[7]
.  
However, with aging the problem of osteoporosis is 
the main causes of disability. Besides the 
aforementioned issues, it should be noted that blood 
transfusion therapy leads to significant side effects. 
One of the most important complications is iron 
overload 
[8]
.  
The major complications caused by iron overload 
including hypogonadism, hyperparathyroidism, 
diabetes mellitus, hypothyroidism and 
cardiomyopathies. Chelation therapy can be used to 
mitigate above iron overload induced complications 
[9]
. 
Ferritin is an iron storage form in the body, which 
releases the required iron when needed. All thalassemia 
patients using iron chelators should be monitored and 
evaluated regarding serum ferritin levels 
[10]
. 
Usually β-Thalassemia major patients will be 
diagnosed at the first years of life. After that, patients 
underwent regular blood transfusion. One year after 
regular blood transfusion, iron chelator had been 
started. Iron deposition may induce bone damage like 
as osteopenia and osteoporosis. The purpose of this 
study was to evaluate the bone density of femoral and 
vertebral column through DUAL ENERGY X RAY 
ABSORPTIOMETRY (DEXA) method in thalassemia 
major patients in age range of 15 to 45 years old and its 
relationship with serum ferritin levels. 
 
 
Methods: 
This case-control study was conducted on 70 
patients with thalassemia major between 15 and 45 
years old. The studied subjects were thalassemia 
patients referred to the Thalassemia Center in Amirkola 
hospital in 2012-2014. The patients were divided into 
two groups (case and control) based on serum ferritin 
levels. There were 35 subjects in each group. The two 
groups were matched regarding age and gender. The 
study inclusion criterion was merely the patients with 
thalassemia major with blood transfusion dependency.  
The study exclusion criteria were as those with 
delayed puberty, hypothyroidism or parathyroid gland 
dysfunction, renal failure, liver failure, growth 
hormone deficiency or person who using vitamin D or 
calcium-D. 
Serum ferritin was measured by ELISA method. 
Osteoporosis diagnosis was performed using Dual 
Energy X-ray Absorptiometry (DEXA), which bone 
density of the spine vertebrates and femoral neck 
region were measured.  
Evaluation of BMD in studied patients was 
performed by a radiologist with Lexxus device, made 
by APELEX Company, France. The mineral density 
was reported in g/Cm2. The comparisons with 
maximum values in similar age and gender group  
(T-Score) or with the average size of individuals of the 
same age and gender (Z-Score) were conducted to 
diagnose osteoporosis. The patients with serum ferritin 
levels higher than 1500 ng/dl were considered as cases, 
and patients with serum ferritin levels lower than 1500 
ng/dl were considered as controls.  
Experiments related to the functionality of other 
glands, liver, kidneys and electrolytes were 
simultaneous performed. Data were analyzed using 
SPSS 20, T-Test, Paired T-Test, x2 and Pearson and 
Spearman coefficients and, and p<0.05 was considered 
significant. 
 
 
Results: 
In overall, 70 patients were evaluated (24 (34.3%) 
males and 46 (65.7%) females). The mean age of 
studied patients was 27.6±4.97 years (15-36 years). 
The background characteristics of patients were shown 
in table 1. The mean age of the case group (ferritin 
levels higher than 1500) and the control group (ferritin 
levels less than 1500) was 28.66±4.59 and 26.54±5.16 
years old, respectively (15-36 years).  
The mean BMD of all patients in the femur and in 
the lumbar spine were 0.79±0.13 g/Cm2 and 0.75±0.14 
g/Cm2, respectively. The prevalence of osteoporosis in 
the lumbar spine and femur of the studied patients were 
48.6% and 20%, respectively. Osteopenia was also 
observed in the lumbar spine of 24 (34.3%) patients 
and in the femur of 33 (47.1%) patients. Similarly, the 
mean serum ferritin level of studied patients was 
2234.91±1213.58 ng/dL. The BMD findings of femur 
in studied patients were normal [23 (32.9%)], 
Osteopenia [33 (47.1%)] and osteoporosis [14 (20%)]. 
And the BMD findings of lumbar were normal [12 
(17.1%)], Osteopenia [24 (34.3%)] and osteoporosis 
[34 (48.6%)].  
The mean serum ferritin level of patients was 
2234.91±1213.58 ng/dl. The mean serum ferritin level 
in patients with femoral osteoporosis was 
2865.31±882.7 ng/dL, while the mean serum ferritin 
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levels in patients with osteopenia and normal density in 
the femur were 2324.56±1361.28 ng/dl and 
1646.05±932.07 ng/dL, respectively (P = 0.001).  
Also, the mean serum ferritin level in patients with 
osteoporotic lumbar vertebrae was 2532.69±1024.42 
ng/dl, while the mean serum ferritin levels in patients 
with osteopenia and normal density in the lumbar spine 
were 2302.87±1500.05 ng/dL and 1236.17±338.16 
ng/dL (P = 0.002), respectively. 
The serum levels of calcium, phosphorus, PTH, 
TSH and T4 in all patients were normal. None of 
patients had the history of bone fractures. 
In addition, femur and spine bone densitometry 
findings are indicated in tables 2 and 3 based on age, 
gender, number of blood transfusions per year, 
chelators used and the proper use of medication by the 
patient. In addition, the correlation between serum 
ferritin and bone densitometry of patients is mentioned 
in figure 1. 
 
Table 1. Bone densitometry findings in patients with thalassemia major: Case&Control Groups. (n=70) 
 
 
 
 
 
 
 
 
 
 Table 2. Characteristics of patients according to the findings of the Femur densitometry 
 
Table 3. Characteristics of patients according to the findings of the lumbar vertebral bone densitometry 
 
Densitometry findings 
Control group 
(Ferritin≤1500) 
Case group 
(Ferritin≥1500) 
Femur L.Vertebrae Femur L.Vertebrae 
Normal 19(54.2%) 12(34.3%) 4(11.4%) 0(0%) 
Osteopenia 15(42.9%) 13(37.1%) 18(51.4%) 11(31.4%) 
Osteoporosis 1(2.9%) 10(28.6%) 13(37.2%) 24(68.6%) 
Total 35(100%) 35(100%) 35(100%) 35(100%) 
Patient Characteristics 
Normal 
N (%) 
Osteopenia 
N (%) 
Osteoporosis 
N (%) 
P-
value 
Age Group 
>26 year old 8 (36.4) 8 (25) 5 (31.5) 
0.665 
≤26 year old 14 (63.6) 24 (75) 11 (68.7) 
Sex 
Male 6 (26.1) 14 (42.4) 4 (28.6) 
0.395 
Female 17 (73.9) 19 (57.6) 19 (71.4) 
Times of blood 
transfusion 
annually 
12-15 times 15 (68.2) 16 (50) 7 (43.7) 
0.264 15-18 times 7 (31.8) 16 (50) 9 (56.3) 
Chelators used 
Osveral+Despheral 14 (63.6) 15 (46.9) 10 (62.5) 
0.392 
Osveral+Despheral+Deferiprone 8 (36.4) 17 (53.1) 6 (37.5) 
Method of Use 
Regular 19(86.4) 20 (62.5) 9 (56.3) 
0.086 
Irregular 3 (13.6) 12 (37.5) 7 (43.7) 
Total 22 (100) 32 (100) 15 (100) - 
Patient Characteristics 
Normal 
N (%) 
Osteopenia 
N (%) 
Osteoporosis 
N (%) 
P-
value 
Age Group 
<26 year old 5 (41.7) 7 (30.4) 9 (25.7) 
0.581 
≥26 year old 7 (58.3) 16 (69.6) 26 (74.3) 
Sex 
Male 4 (33.3) 9 (37.5) 11 (32.4) 
0.918 
Female 8 (66.7) 15(62.5) 23 (67.6) 
Times of blood 
transfusion 
annually 
12-15 times 10 (83.3) 13 (56.5) 15 (42.9) 
0.051 15-18 times 2 (16.7) 10 (43.5) 20 (57.1) 
Chelators used 
Osveral+Despheral 5 (41.7) 14 (60.9) 20 (57.1) 
0.539 
Osveral+Despheral+Deferiprone 7 (58.3) 9 (39.1) 15 (42.9) 
Method of Use 
Regular 10 (83.3) 18 (78.3) 20 (57.1) 
0.114 
Irregular 2 (16.7) 5 (21.7) 15 (42.9) 
Total 12 (100) 23 (100) 35 (100) - 
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Fig 1.Correlation between serum ferritin level and densitometry findings in the study groups (n= 70) 
 
 
Discussion: 
Our study showed a significant and indirect 
relationship between serum ferritin levels and bone 
density of femoral and lumbar region. Iron deposion 
may be a cause of bone damage. And our study 
suggests that the serum ferritin levels in studied 
patients can be an appropriate indicator of bone density 
estimation, and maybe prediction of fractures.  
Mean serum ferritin levels in patients with 
osteoporosis of the lumbar spine were 2532.69±1024.42 
ng/dL, while the mean serum ferritin levels in patients 
with osteoporosis and normal BMD of the lumbar spine 
were 2302.87±1500.05 ng/dL and 1236.17±338.16 
ng/dL (P=0.002), respectively (figure 1). 
Karimi et al.s showed no significant association 
between BMD and Bone Mineral Content (BMC) with 
biochemical and hematological parameters, but both 
parameters correlated significantly with hemoglobin 
level. In clinical-pathological evaluations, the serum 
levels of calcium, phosphorus, alkaline phosphatase, 
hemoglobin and ferritin were measured. In their study, 
the mean age of patients was 13-14 years old,
 [11]
 while 
in the current study; the mean age was about 27. 
Similarly, the average spine BMD in patients with 
thalassemia major was significantly lower than the 
control group (0.60±0.08 and 0.76±0.05 g/Cm2, 
respectively).  
However, there were no significant differences on 
BMD between beta thalassemia and thalassemia 
intermedia groups. The mean BMD in patients with 
thalassemia major having hemoglobin levels greater 
than 10 mg/dL was significantly lower, but other 
biochemical and hematological parameters as well as 
blood transfusion events, gender and therapeutic 
chelators showed no impact on BMD similar to our 
study
.[11]
.  
Although in other study a correlation between the 
height, age and BMD were found
 [12]
. Also, in 
Shamshirsaz et al.'s study, the bone density disorders of 
lumbar spine were correlated with chelating therapy 
duration. This difference could be due to a greater 
number of studied patients in the study. In this study 
conducted on 220 patients with thalassemia major, zinc 
blood levels showed a significant relationship with 
lumbar spine bone density 
[13]
.  
In another study in Turkey that was done on 25 
patients with thalassemia major with an average age of 
18 years in 2004, the bone density of the lumbar spine 
and proximal femur were measured using Dual X-ray 
Absorptiometry method. In this study, the bone density 
of the lumbar vertebral column (0.633±0.168) and 
femoral bones (0.695±0.119) in the patient group 
showed significant differences compared to the 
controls (0.851±0.146 and 0.785±0.130, respectively). 
[14]
 
Examining bone related disorders in 18 patients 
with thalassemia showed a significant correlation 
between serum ferritin levels and the bone density 
between control (1.15±0.25) and patient (0.86±0.03) 
groups. In this study, the amounts of potassium, 
phosphate and serum ferritin in the patients group were 
4.5±0.05 mEq/liter, 3.72±0.09 mg/dl and 1366.6±253.9 
ng/ml, respectively. The same values for the control 
group were 3.6-5, 2.79-4.342 and 50-100, respectively 
[4]
. 
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Unlike previous studies, in a study on children with 
beta -thalassemia, no significant relationship was found 
between BMD and serum ferritin levels. This can be 
due to small sample size, measurement errors or 
chelating therapy type. Another possible reason to 
explaining the lack of significant correlation between 
serum ferritin levels and bone density is the possible 
serum ferritin tolerance. In these experiments, serum 
ferritin levels were measured at a given moment, and 
its changes at different times were not determined. 
However, a significant shorter height, lower sexual 
maturity, and lower density values were seen in the 
patient group 
[15]
. 
These results confirmed another study by Jensen et 
al. on 82 thalassemia patients (44 women with the 
mean age of 27 years, 38 males with the mean age of 
25 years). In this study, the mean serum ferritin level at 
the time of study was 2733 mg/l, showing no 
significant association in patient group compared with 
control group (with a standard deviation of 5798 mg/l 
for serum ferritin levels), although there was a 
significant relationship between gender (male) and the 
severity of low bone mass 
[9]
. 
Arjmandi et al. during 2004-2006 performed a 
study on 273 patients with thalassemia major (137 
males and 136 females) and 32 patients with 
thalassemia intermedia (13 males and 19 females). The 
mean age was 14±6.5 and 13.4±6.5 years, respectively. 
They examined the relationship between BMD and 
biochemical and hematological parameters. In this 
study, no significant difference was found between 
osteoporosis patients and the control group regarding 
Height Standard Deviation Score (HSDS). This study 
showed correlation of bone density with serum ferritin 
levels in the radius region. Similarly, no significant 
correlation was found between bone density and serum 
levels of calcium, zinc, phosphorus, and magnesium 
[16]
. 
Patients with thalassemia are prone to various 
conditions including bone disorders. Health 
maintenance of bone tissue in such patients is subject 
to assessment of the bones health with a technique, 
which should be highly accurate and reliable, easy to 
use and inexpensive. 
In conclusion, the current study was showed 
significant differences between the mean serum ferritin 
levels in patients with thalassemia major and different 
bone mineral densities (normal, osteopenia, and 
osteoporosis). Thus, the patients with thalassemia 
major with lower bone density had significant higher 
serum ferritin levels compared to the patients with 
normal bone density. We recommended to more study 
of correlation between serum ferritin levels and bone 
density in people with thalassemia to assess bone 
health by this mentioned serum index.  
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